PYXIS ONCOLOGY INC (PYXS)

Company Profile

Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company is headquartered in Boston, Massachusetts and currently employs 67,000 full-time employees. The company went IPO on 2021-10-08. The firm is focused on developing a multi-modality portfolio of therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The company has developed a portfolio that includes antibody drug conjugate (ADC), product candidates, immuno-oncology (IO), product candidates, and monoclonal antibody (mAb), preclinical discovery programs that it is developing as monotherapies and in combination with other therapies. Its product pipelines include PYX-201, PYX-106 and PYX-107. Its ADC product candidate is PYX-201, an investigational, novel ADC consisting of an Immunoglobulin G1 (IgG1), anti-fibronectin Extradomain-B, mAb site-specifically conjugated to an auristatin derivative via a cathepsin B-cleavable linker. Its IO product candidate is PYX-106, an investigational, fully human IgG1 isotype Siglec-15-targeting antibody designed to block Siglec-15 mediated suppression of T-cell proliferation and function.

Company Info

PYXIS ONCOLOGY INC

321 Harrison Avenue, 11th Floor, Suite 1

Boston MASSACHUSETTS

P: 16174533596

Employees: 67000

Website: https://pyxisoncology.com/